Webinar: Mechanistic static models for quantitative predictions of CYP- and Transporter-Mediated DDI by Elsevier

Host Login

Mechanistic static models for quantitative predictions of CYP- and Transporter-Mediated DDI

About

Physiologically based pharmacokinetic (PBPK) models play a crucial role in clinical drug development, particularly for assessing the risk of drug–drug interactions (DDIs). Traditionally, mechanistic static models (MSMs) are used in the early screening phase, while dynamic PBPK models provide detailed, quantitative DDI predictions for regulatory submissions. However, developing and reviewing PBPK models demands significant resources.
Recent studies suggest that MSMs, when using appropriate precipitant concentrations, can offer quantitative predictions comparable to PBPK models. This presents an opportunity to take a pragmatic approach—leveraging the strengths of both MSM and PBPK models. MSM can be utilized for efficient DDI risk screening, while PBPK models can be reserved for more complex scenarios, such as dose-staggering analyses and extrapolating DDI effects across diverse populations.
Join our webinar to explore how these models can be applied strategically to optimize resources, reduce development timelines, and enhance DDI predictions.

Presenters

Olivier Barberan

Director, Translational Medicine Solutions , Elsevier

Olivier Barberan is currently Director of Translational Medicine Solutions at Elsevier with more than 20 years of experience in the pharmaceutical industry and 15 years in product development leading to more than 40 peer review articles and short communications. He was previously Senior Product Manager of Reaxys Medicinal Chemistry at Elsevier. Following an Engineer degree in Chemistry at Ecole Centrale Marseille in 1996 and a PhD in Therapeutic Chemistry related to VEGF involvement in diabetic retinopathy at the University of Paris in 2000, he joined Aureus Sciences and held Project Manager positions for several fields including Kinase, GPCR, ADME/DDI. In 2006, he was appointed to a Director of Product Development position. After the acquisition of Aureus Sciences in 2013 by Elsevier, he moved into a new position in Elsevier Life Science group as Senior Product Manager of Reaxys Medicinal chemistry. In 2017, he was appointed as Director of translational medicine and responsible of the development of Pharmapendium as well as a new version a predictive tool for drug interactions involving cytochromes and UGTs based on in vitro in vivo extrapolation. 

Sheila Peters

Executive Director and Early Asset Lead, Boehringer Ingelheim

Dr. Sheila Annie Peters has a PhD in Chemistry. She started her career in Pharma
R&D in 1999, working at Cyprotex, UK. Later, she joined AstraZeneca, Mölndal,
where she developed and applied a generic whole-body PBPK model to support drug
discovery and early development projects across different R&D sites. Here, she won
the AstraZeneca Innovative Medicines Science Award for the “Design and
Development of LungSim Simulation tool for Inhalation PK Modelling”. Sheila served
as Head of Translational Quantitative Pharmacology group at Merck KGaA,
Darmstadt for 6 years before taking her current position as Early Asset Lead at
Boehringer Ingelheim. Sheila is the EFPIA Topic leader for the ICH M12 group
focused on harmonizing drug-drug interaction (DDI) guidelines. She has published
several papers on PK, PBPK, human dose predictions, gut metabolism and DDI in
high impact journals and authored a book on PBPK.

Full name*

Email Address*

Institution*

Job Title*

Country*